Our results indicated that expression levels of miR-29b, miR-125a-5p, miR-205, and miR-221 may be useful as diagnostic markers of sensitivity to Gem treatment, and that PIK3R1 and MMP-2 could become molecular targets of anti-tumor therapies for patients with CCA. This evidence concerns the gene MMP2 and cholangiocarcinoma.